Keywords: Bayer, Patent appeal, Nexavar, India, MSF, Compulsory licensing

Bayer attempts to block generic Nexavar in India again slammed by MSF

Article | 04 September 2012

Print This

German drug major Bayer (BAYN: DE) yesterday headed to India’s Intellectual Property Appellate Board in Chennai in a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in